Qyuns Therapeutics Co., Ltd.

江苏荃信生物医药股份有限公司

02509.HK

Clinical-stage biotech developing biologic therapies for autoimmune and allergic diseases in China. Lead candidates include QX002N, an IL-17A inhibitor in Phase III for ankylosing spondylitis, and QX005N, an IL-4R monoclonal antibody in Phase II trials, with nine pipeline candidates.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Connected or related major customers / suppliers
• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Capacity and utilisation
• Losses and path to profitability
• Cash burn and runway
• Working capital: receivables, prepayments and cash cycle
• Preferred shares and fair-value liabilities
• Investments and fair-value assets
• Non-recurring gains and losses
• Related-party transactions and balances
• Chapter 18A biotech